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The intrinsic innervation of the gastrointestinal (GI) tract is comprised of en-
teric neurons and glia, which are buried within the wall of the bowel and orga-
nized into two concentric plexuses that run along the length of the gut forming
the enteric nervous system (ENS). The ENS regulates vital GI functions includ-
ing gut motility, blood flow, fluid secretion, and absorption and thus maintains
gut homeostasis. During vertebrate development it originates predominantly
from the vagal neural crest (NC), a multipotent cell population that emerges
from the caudal hindbrain region, migrates to and within the gut to ultimately
generate neurons and glia in response to gut-derived signals. Loss of GI inner-
vation due to congenital or acquired defects in ENS development causes enteric
neuropathies which lack curative treatment. Human pluripotent stem cells (hP-
SCs) offer a promising in vitro source of enteric neurons for modeling human
ENS development and pathology and potential use in cell therapy applications.
Here we describe in detail a differentiation strategy for the derivation of enteric
neural progenitors and neurons from hPSCs through a vagal NC intermediate.
Using a combination of instructive signals and retinoic acid in a dose/time de-
pendent manner, vagal NC cells commit into the ENS lineage and develop into
enteric neurons and glia upon culture in neurotrophic media. © 2021 The Au-
thors. Current Protocols published by Wiley Periodicals LLC.
Basic Protocol 1:Generation of vagal neural crest/early ENS progenitors from
hPSCs
Basic Protocol 2: Differentiation of hPSC-derived vagal NC/early ENS pro-
genitors to enteric neurons and glia
Keywords: ENS progenitors  human pluripotent stem cells  hPSCs  vagal
neural crest
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INTRODUCTION
The enteric nervous system (ENS) is a complex and elegantly shaped network of neu-
rons and supporting glial cells which provides the intrinsic gut innervation to control
a plethora of bowel functions, such as intestinal motility, fluid secretion, movement
across the epithelium, and vascular tone (Furness, 2012). The ENS is organized into
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ganglionated structures forming two major plexuses, the myenteric and submucosal
plexus, located within the wall of gastrointestinal (GI) tract and extending longitudi-
nally (Furness, 2006). During early embryonic development, the majority of enteric gan-
glia develops from the vagal neural crest (NC; Anderson, Stewart, & Young, 2006; Le
Douarin & Teillet, 1973). Vagal NC is a transient multipotent cell population emerging
from the dorsal tip of the neural tube at the level of somites 1 to 7 and is marked by the
expression of HOX gene paralogous groups (PG) 3-5 (Burke, Nelson, Morgan, & Tabin,
1995; Chan et al., 2005; Fu, Lui, Sham, Cheung, & Tam, 2003; Kam& Lui, 2015). Apart
from generating most of the ENS, vagal NC cells also contribute to cardiovascular sys-
tem structures, lung, thymus, and pancreas (Hutchins et al., 2018; Le Douarin, Creuzet,
Couly, & Dupin, 2004). Following delamination, vagal NC cells emigrate to the gut, a
process partially orchestrated by somite-derived retinoic acid (RA; Niederreither et al.,
2003; Simkin, Zhang, Rollo, & Newgreen, 2013; Uribe, Hong, & Bronner, 2018), and
commit to a developmental program, which involves highly coordinated events such as
progressive ENS progenitor specification and proliferation, rostro-caudal migration, and
differentiation towards neurons and glia (reviewed in Kang, Fung, & Vanden Berghe,
2021; Lake & Heuckeroth, 2013). Dysregulation of these processes could result in ab-
sence or dysfunction of enteric ganglia along various lengths of the intestine, a common
cause of enteric neuropathies such as Hirschsprung’s disease (HSCR; Heanue & Pachnis,
2007; Obermayr, Hotta, Enomoto, & Young, 2013).
Seminal findings on the persistence of enteric neural progenitor cells in the fetal and
post-natal gut offer an autologous cell therapy as a promising strategy to treat enteric
neuropathies (Burns & Thapar, 2014). However, limiting factors such as the need for a
sufficient pool of ENS progenitors that could be harvested have set a roadblock to this
therapeutic approach. Human pluripotent stem cells (hPSCs) offer an alternative, acces-
sible, and infinite source of such progenitor cells (reviewed in Stamp, 2017) and a num-
ber of hPSC differentiation strategies for the production of ENS progenitors and their
derivatives have been reported over the past few years (Barber, Studer, & Fattahi, 2019;
Fattahi et al., 2016; Lai et al., 2017; Lau et al., 2019; Li et al., 2018; Schlieve et al., 2017;
Workman et al., 2017). We have recently described the generation of NC populations cor-
responding to various levels along the anteroposterior (A-P) axis from hPSCs, including
vagal NC (Frith et al., 2018). Based on this, we developed a step-by-step differentiation
Figure 1 Overview of the differentiation protocol for the generation of ENS progenitors and enteric
neurons/glia from hPSCs. (A) Schematic of the step-wise differentiation process for the generation
and maturation of ENS progenitors from hPSC-derived vagal NC. (B) Representative brightfield
images corresponding to different stages of the protocol. ENS, enteric nervous system; hPSCs,




strategy for the generation of ENS progenitors via an hPSC-derived vagal NC intermedi-
ate (Frith et al., 2020). Our approach relies on the induction of a HOX-negative NC pop-
ulation with a default cranial identity (Hackland et al., 2017), expressing SOX10, PAX3,
PAX7, which is subsequently steered toward a caudal hindbrain/cervical axial identity, re-
flected by the upregulation of HOX PG members (3-5), following exposure to RA (Frith
et al., 2018; Frith et al., 2020). Moreover, we found that RA treatment drives the acquisi-
tion of an ENS progenitor identity marked by the induction of ASCL1, PHOX2B. These
vagal NC/early ENS progenitors can colonize and differentiate efficiently within the ENS
of adult mice following transplantation and thus serve as an attractive cell population for
use in cell therapy approaches aiming to treat enteric neuropathies such as HSCR (Frith
et al., 2020). Here we provide a detailed description of the protocol for their in vitro pro-




GENERATION OF VAGAL NEURAL CREST/EARLY ENS PROGENITORS
FROM hPSCs
The differentiation protocol (Fig. 2A) begins with plating hPSCs into a culture regime
that allows precise control of BMP signaling levels, achieved by simultaneous treatment
with BMP4 recombinant protein along with a BMP type-I receptor inhibitor (DMH-1,
an approach dubbed as Top-Down inhibition; Hackland et al., 2017), WNT signaling
activation through GSK-3 inhibition mediated by the WNT agonist CHIR99021, and
TFG-β pathway inhibition by employing the ALK receptor inhibitor SB431542. Follow-
ing 4 days of treatment, the resulting population displays an anterior/cranial NC charac-
ter reflected by the upregulation of SOX10, PAX3, PAX7, p75, and the lack of HOX gene
expression. Medium supplementation with RA during days 4 to 6 induces a vagal axial
identity marked by the upregulation of the corresponding HOX genes (HOXB4, HOXB5),
a step which coincides with the acquisition of an ENS precursor character as evidenced
by ASCL1, PHOX2B expression.
Materials
Human pluripotent stem cells (hPSCs), e.g., cell lines used for this study: hESC
line H9 (WA09), see Thomson
et al., 1998 and H9SOX10:GFP, see Chambers et al., 2012
Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 Ham (DMEM/F12;
Merck Life Science, cat. no. D6421; store at 4°C)
mTeSRTM1 (Stemcell Technologies, cat. no. 85850; prepare as per manufacturer’s
instructions)
ReLeSRTM (Stemcell Technologies, cat. no. 05873; store at room temperature)
Dulbecco’s Phosphate Buffered Saline (Merck Life Science, cat. no. D8537; store
at room temperature)
N2 Supplement (Thermo Fisher Scientific, cat. no. 17502048; aliquot and store at
−20°C; minimize freeze-thaw cycles)
GlutaMAXTM Supplement (Thermo Fisher Scientific, cat. no. 35050038; store at
4°C)
MEM Non-Essential Amino Acids Solution (Thermo Fisher Scientific, cat. no.
11140050; store at 4°C)
CHIR99021 (Tocris, cat. no. 4423; aliquot and store at −20°C; minimize
freeze-thaw cycles)
SB 431542 (Tocris, cat. no. 1614; aliquot and store at −20°C; minimize
freeze-thaw cycles)
Human BMP4 Recombinant Protein (Thermo Fisher Scientific, cat. no. PHC9534;
aliquot and store at −20°C; minimize freeze-thaw cycles)
DMH-1 (Tocris, cat. no. 4126; aliquot and store at −20°C; minimize freeze-thaw
cycles) Gogolou et al.
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Figure 2 Vagal NC/early ENS progenitor induction from hPSCs. (A) Diagram depicting the culture
regime and the timeline followed during Basic Protocol 1. (B) Low-power and high-power (mag-
nified) images taken daily during monolayer vagal NC induction showing cell morphology and
confluency as the protocol progresses. (C) qPCR expression analysis of indicated vagal NC/ENS
progenitor genes and (D) members of HOX group that correspond to vagal A-P levels.Error bars in-
dicate standard deviation of 3 individual biological replicates. (E) Quantitative assessment of vagal
NC differentiation using flow cytometry following staining with the SOX10 and the low-affinity nerve
growth factor receptor (p75) or the surface antigen CD49d. P3X was used as negative control;
p75++ gate indicates high p75 expression. NC, neural crest; ENS, enteric nervous system; hPSCs,
human pluripotent stem cells; RQ, Relative Quantification; hESCs, human embryonic stem cells;




Penicillin-Streptomycin (5,000 U/ml; Thermo Fisher Scientific, cat. no. 15070063;
aliquot and store at −20°C as per manufacturer’s instructions)
Y-27632 2HCl (AdooQ Bioscience, cat. no. A11001; aliquot and store at −20°C;
minimize freeze-thaw cycles)
All-trans retinoic acid (RA; Merck Life Science, cat. no. R2625; stock solution of
10-2 M in DMSO: store at −80°C; prepare and store aliquots of 10-3 M in
DMSO at −20°C in light protected vials; dilute retinoic acid with tissue culture
medium right before use in subdued light)
GeltrexTM LDEV-Free Reduced Growth Factor Basement Membrane Matrix
(Thermo Fisher Scientific, cat. no. A1413202; defrost as per manufacturer’s
instructions; make stock aliquots and store at −20°C for up to 18 months from
date of manufacture; store unused diluted GeltrexTM Matrix solution, 1% final
concentration, at 4°C for up to 1 week)
Accutase® solution (Merck Life Science, cat. no. A6964; prepare 25 ml aliquots
and store at −20°C; once defrosted, store at 4°C)
Neural crest basal medium (see recipe, Table 1)
Neural crest induction medium (see recipe, Table 2)
Biosafety cabinet
Incubator maintained at 37°C with 95% humidified atmosphere and 5% CO2 levels
Centrifuge (Thermo Fisher Scientific Heraeus Megafuge 1.0)
Inverted microscope (Olympus CKX41)
Fluorescence Olympus inverted microscope 1X53
InCell Analyser 2200 (GE Healthcare)
Applied Biosystems QuantStudioTM 12K Flex thermocycler (Thermo Fisher
Scientific)
BD FACSJazz (BD Biosciences)
Neubauer Improved Hemocytometer Counting Chamber (Hawksley)
Single channel pipets and tips
Pipet controller and serological pipets
Cell culture plasticware and consumables: 15-, 50-ml conical tubes; multi-well
plates and T12.5 flasks; syringes; syringe filters, 0.22 μm; filtration units; glass
pipets
NOTE: Tissue culture operations are carried out using aseptic technique and sterile han-
dling.
hPSC culture and maintenance
1. Culture hPSCs in mTeSRTM1 on Geltrex-coated T12.5 flasks.
Subculture newly thawed lines for several passages (at least four) before differentiation.






concentration Volume for 50 ml
DMEM/F12 1× Not applicable 48.5 ml
N2 supplement 100× 1× 0.5 ml
MEM non-essential
amino acids solution
100× 1× 0.5 ml
GlutaMAX supplement 100× 1× 0.5 ml
aPenicillin-streptomycin can be added in the basal medium (final concentration 1×) to prevent bacterial contamination.











concentration 10 ml 25 ml 50 ml
Neural crest basal Not applicable Not applicable 10 ml 25 ml 50 ml
CHIR99021 10 mM 1 µΜ 1 µl 2.5 µl 5 µl
DMH-1 10 mM 1 µΜ 1 µl 2.5 µl 5 µl
SB 431542 10 mM 2 µΜ 2 µl 5 µl 10 µl
BMP4 50 µg/ml 20 ng/ml 4 µl 10 µl 20 µl
All-trans retinoic acid
(only add between Day
4-Day 6)
b
1 mM 1 µΜ 10 µl 25 µl 50 µl
aWe recommend that neural crest induction medium is made fresh on the day of feeding. At Day 0, when hPSCs are plated into neural
crest induction conditions Y-27632 2HCl, a Rho-associated coil kinase (ROCK) inhibitor, must be added at a final concentration of 10
µM to help cell attachment and increase cell survival.
bAll-trans retinoic acid is light sensitive, so work in the dark and keep medium out of direct light.
2. Passage hPSC cultures every 4-5 days until they reach 80%-85% confluency using
ReLeSRTM, as described in the protocol provided from Stemcell Technologies.
Passaging ratios may vary between 1:6 and 1:12. For increased NC yield, passage cells
at a high ratio twice per week.
ReLeSRTM-based passaging yields higher NC efficiency compared to EDTA-based dis-
sociation solution.
Prior to differentiation
3. Monitor cells through an inverted microscope. Grow cultures to ∼80%-85% conflu-
ency for an optimal NC induction (Fig. 2B).
4. Before starting the differentiation, coat plates with Geltrex:
a. Thaw a Geltrex aliquot on ice to prevent unwanted gelling when handling small
volumes.
b. Dilute Geltrex 1:100 in pre-chilled DMEM/F12 (4°C), i.e., 200 µl Geltrex in
20 ml DMEM/F12.
c. Transfer sufficient Geltrex solution to each well of a multi-well plate, i.e., 100-
200 µl Geltrex solution per cm2 is enough to coat the growth surface.
d. Incubate Geltrex-coated plates at 37°C for a minimum of 1 hr. Alternatively,
coated plates can be stored at 4°C for up to 2 weeks when sealed with Parafilm
to prevent them from drying out.
5. Prepare neural crest basal medium (see Table 1).
6. Prepare neural crest induction medium by supplementing neural crest basal medium
with small molecules and mix thoroughly (see Table 2).
Differentiation of hPSCs into vagal NC cells/early ENS progenitors (6 days in total)
7. Day 0: Plating hPSCs for neural crest differentiation:
a. Grow hPSCs until they reach ∼80%-85% confluency.
b. Aspirate mTeSRTM1 medium from the flask and add 1× PBS (200 µl/cm2) to
wash cell colonies. Remove PBS.
c. Add Accutase solution (100 µl per cm2) and incubate at 37°C for 5-7 min. Ob-





Figure 3 Comparison of hPSCs plated at an optimal (upper row) and non-optimal (bottom row)
seeding density during NC induction. A sub-optimal seeding density yields lower efficiency and
impure NC cultures that aremorphologically distinct and appear as flat and dense colonies (dashed
circle) neighboring NC cells that display a stellate-like morphology (arrows). Scale bar = 50 µm.
hPSCs, human pluripotent stem cells; NC, neural crest.
d. Neutralize Accutase solution by adding pre-warmed DMEM/F12 medium and
triturate cells using a serological pipet in order to dissociate them into a single-
cell suspension.
e. Transfer cell suspension to a conical centrifuge tube.
Cells are lifted up in suspension. Do not aspirate Accutase solution as this will result in
losing the cell population.
f. Agitate conical tube to ensure adequate mixing and transfer 10µl cell suspension
to a hemocytometer.
g. Count cells using the hemocytometer.
h. Meanwhile centrifuge cell suspension at 300 × g for 4 min at room temperature.
i. After centrifugation, aspirate supernatant carefully and dislodge cell pellet in
neural crest induction medium supplemented with 10 µM Y-27632 2HCl (see
Table 2).
We recommend resuspending cells at a ratio of 1 million cells per ml.
j. Plate cells at a density of 30,000 to 40,000 cells per cm2 on a Geltrex pre-coated
plate in neural crest induction medium supplemented with 10µMY-27632 2HCl.
That is, plate 30 µl of cell suspension (∼30,000 cells) per cm2.
For a well of a 6-well plate with a surface area of ∼10 cm2, transfer 300 µl of cell
suspension.
Cell density is very critical for neural crest differentiation efficiency and it is cell line
dependent. We highly recommend performing cell density titration for every cell line used
to ensure optimal yield. Representative images of non-NC like cells compromising the
protocol’s efficiency due to inefficient seeding density are displayed in Figure 3.
k. Following cell plating, top up each well with neural crest induction medium sup-
plemented with 10 µM Y-27632 2HCl to obtain a final volume of 200 µl per
cm2.
l. Place cells in a 37°C incubator and move plate back and forth, side to side to
ensure cells are evenly distributed throughout the growth surface.
m. Incubate cells at 37°C in a humidified atmosphere of 5% CO2 in air.
Do not disturb the cells until they have attached to the bottom of the plate.




a. Feed cells by aspirating old medium and adding 200 µl freshly made neural crest
induction medium without Y-27632 2HCl per cm2. Always add medium down
the side wall of the well and not directly on top of the cell colonies.
By Day 2, cells form spider’s-web like colonies and exhibit a spread out, spiky charac-
teristic morphology due to treatment with Y-27632 2HCl (Fig. 2B).
b. Incubate cells at 37°C for 48 hr.
9. Day 4 (vagal axial patterning and ENS specification):
a. Supplement neural crest induction medium with 1 µM all-trans retinoic acid.
b. Replace culture medium with freshly made and supplemented medium
(200 µl/cm2).
Retinoic acid is extremely sensitive to light and high temperature; do not warm upmedium
with retinoic acid and keep plate out of light.
At Day 4, cells reach ∼95% of confluency (Fig. 2B), an indicator of the success of the
protocol. If cells are under confluent at this point, it is very likely that the differentiation
will not work.
c. Incubate cells at 37°C for 24 hr.
10. Day 5:
a. Refresh medium with 200 µl per cm2 of freshly made neural crest induction
medium supplemented with 1 µM all-trans retinoic acid.
We found that replacing medium at this stage to ensure sufficient levels of retinoic acid
is important to maintain the expression of retinoic acid induced ENS progenitor genes
ASCL1, PHOX2B.
Do not be alarmed by the increased cell death following treatment with retinoic acid; it
is part of the process.
Cells begin to look darker and spiky after treatment with retinoic acid (Fig. 2B).
b. Incubate cells at 37°C for 24 hr.
11. Day 6:
a. End of vagal neural crest differentiation: Cells cover 95%-100% of the growth
surface forming a monolayer, appear dark and spiky (Fig. 2B).
b. Cells are ready for replating in non-adherent conditions prior to the generation of
enteric neurons and glia (see Basic Protocol 2).
Optional: Assess vagal neural crest induction by flow cytometry, immunocytochemistry,
or quantitative polymerase chain reaction (qPCR; for details about experimental tech-
niques refer to Frith et al., 2018; Frith et al., 2020).
Understanding results
At the end of the differentiation, vagal NC cells/early ENS progenitors should form an
almost confluent monolayer, exhibiting stellate-like morphology and appearing darker
compared to hPSCs. The characteristic morphology of the cells as the NC protocol pro-
gresses is depicted in Figures 2B and 3. The efficiency of NC induction is indicated by
the upregulation of NC-associated transcripts such as SOX10, PAX3, PAX7, and TFAP2A
as well as ENS progenitor markers (e.g., ASCL1, PHOX2B; Fig. 2C and Table 3). The
acquisition of a vagal axial identity can be verified by the marked increase in the expres-
sion HOX PG (3-5) transcripts (e.g., HOXB4, HOXB5; Fig. 2D). At this stage we also
found that typically around 45%-65% of cells are positive for SOX10 protein follow-
ing intracellular staining and analysis by flow cytometry and this SOX10+ population
also co-expresses high levels of p75 (Hackland et al., 2017; Fig. 2E and Table 4) and the




Table 3 List of Primers Used for Vagal Neural Crest/Early ENS Progenitor Characterization
Gene Forward Reverse Roche UPL probe
GAPDH 5′-agccacatcgctcagacac-3′ 5′-gcccaatacgaccaaatcc-3′ # 60
SOX10 5′-ggctcccccatgtcagat-3′ 5′-ctgtcttcggggtggttg-3′ # 21
PAX3 5′-aggaggccgacttggaga-3′ 5′-cttcatctgattggggtgct-3′ # 13
PAX7 5′-gaaaacccaggcatgttcag-3′ 5′-gcggctaatcgaactcactaa-3′ # 66
ASCL1 5′-cgacttcaccaactggttctg-3′ 5′-atgcaggttgtgcgatca-3′ # 38
PHOX2B 5′-ctaccccgacatctacactcg-3′ 5′-ctcctgcttgcgaaacttg-3′ # 17
TFAP2A 5′-aacatgctcctggctacaaaa-3′ 5′-aggggagatcggtcctga-3′ # 62
HOXB1 5′-ccagctagggggcttgtc-3′ 5′-atgctgcggaggatatgg-3′ # 39
HOXB2 5′-aatccgccacgtctcctt-3′ 5′-gctgcgtgttggtgtaagc-3′ # 70
HOXB4 5′-ctggatgcgcaaagttcac-3′ 5′-agcggttgtagtgaaattcctt-3′ # 62
HOXB5 5′-aagcttcacatcagccatga-3′ 5′-cggttgaagtggaactccttt-3′ # 1
HOXB7 5′-ctacccctggatgcgaag-3′ 5′-caggtagcgattgtagtgaaattct-3′ # 1
HOXC9 5′-gcagcaagcacaaagagga-3′ 5′-cgtctggtacttggtgtaggg-3′ # 85
Table 4 Antibody List Used for Flow Cytometry Analysis of Vagal Neural Crest/Early ENS
Progenitors
a
Antibody Company Catalog number Species Class
Anti-CD49d BioLegend 304302 Mouse Monoclonal
Anti-SOX10 Cell Signaling Technology 89356 Rabbit Monoclonal
Anti-p75 Cell Signaling Technology 8238 Rabbit Monoclonal
a
Working dilutions have to be optimized depending on antibody data using a series of dilutions in a titration experiment.
BASIC
PROTOCOL 2
DIFFERENTIATION OF hPSC-DERIVED VAGAL NC/EARLY ENS
PROGENITORS TO ENTERIC NEURONS AND GLIA
The protocol (Fig. 4A) continues with re-plating vagal NC cells generated from 2D
monolayer differentiation into non-adherent conditions that promote formation of 3D
cell sphere aggregates. These are then subsequently re-plated in adherent conditions and
in the presence of neurotrophic medium to promote further differentiation toward ENS
components. During that stage, SOX10+ progenitor cells migrate out of the re-plated
spheres to give rise to enteric neurons and glia. The emergence of neurons, marked by
downregulation of SOX10 and induction of neural markers, precedes glial occurrence,
which is accompanied by sustained expression of SOX10 and upregulation of glial mark-
ers.
Materials
Vagal NC cells (from Basic Protocol 1)
Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 Ham (Merck Life
Science, cat. no. D6421; store at 4°C)
NeurobasalTM Medium (Thermo Fisher Scientific, cat. no. 21103049; store at 4°C)
Dulbecco’s Phosphate Buffered Saline (Merck Life Science, cat. no. D8537; store
at room temperature)
N2 Supplement (Thermo Fisher Scientific, cat. no. 17502048; aliquot and store at
−20°C; minimize freeze-thaw cycles)
B27 Supplement (Thermo Fisher Scientific, cat. no. 17504001; aliquot and store at




Figure 4 (A) Diagram depicting the culture conditions used for the generation of enteric neurons
and glia and representative brightfield images corresponding to different stages of Basic Protocol
2. (B) Immunofluorescence analysis at day 12 showing neurons and ENS progenitors expressing
TUJ1 and SOX10:GFP, respectively to migrate out of the spheres. (C) Immunofluorescence anal-
ysis of the expression of the progenitor marker SOX10:GFP and the neural markers TRKC and
TUJ1 at day 17. (D) Immunofluorescence analysis of the expression of the ENS progenitor/early
glial markers SOX10:GFP, S100β and the pan/neural markers HuCD, PERIPHERIN, NF-H at day
22 of the protocol. (E) Immunofluorescence images showing neurons expressing PERIPHERIN
and TUJ1 at day 55. Cells were derived using a SOX10:GFP reporter line (Chambers et al., 2012).




GlutaMAXTM Supplement (Thermo Fisher Scientific, cat. no. 35050038; store at
4°C)
MEM Non-Essential Amino Acids Solution (Thermo Fisher Scientific, cat. no.
11140050; store at 4°C)
CHIR99021 (Tocris, cat. no. 4423; aliquot and store at −20°C; minimize
freeze-thaw cycles)
Recombinant Human FGF basic (146 aa) protein CF (R&D Systems, cat. no.
233-FB/CF; reconstitute powder following manufacturer’s instructions, aliquot
and freeze at −20°C; minimize freeze-thaw cycles)
5,000 U/ml Penicillin-Streptomycin (Thermo Fisher Scientific, cat. no. 15070063;
aliquot and store at −20°C as per manufacturer’s instructions
Y-27632 2HCl (AdooQ Bioscience, cat. no. A11001; aliquot and store at −20°C;
minimize freeze-thaw cycles)
Accutase® solution (Merck Life Science, cat. no. A6964; make 25 ml aliquots and
store at −20°C; once defrosted, store at 4°C)
Sphere culture basal medium (see recipe, Table 5)
Complete sphere culture medium (see recipe, Table 6)
BrainPhysTM Neuronal Medium (Stemcell Technologies, cat. no. 05790; store at
4°C)
Recombinant human glial cell-derived neurotrophic factor (GDNF; PeproTech, cat.
no. 450-10; reconstitute powder as per manufacturer’s instructions, aliquot, and
store at −20°C; minimize freeze-thaw cycles)
(2S)-N-[(3,5-Difluorophenyl)acetyl]-L-alanyl-2-phenyl]glycine 1,1-dimethylethyl
ester (DAPT; γ-secretase inhibitor; Tocris, cat. no. 2634; aliquot and store at
−20°C; minimize freeze-thaw cycles)
L-Ascorbic acid 2-phosphate sesquimagnesium salt (Santa Cruz Biotechnology,
cat. no. sc-228390; reconstitute powder as per manufacturer’s instructions,
aliquot, and store at −20°C; minimize freeze-thaw cycles)
Vitronectin (VTN-N) Recombinant Human Protein, Truncated (Thermo Fisher
Scientific, cat. no. A14700; prepare 100 µl aliquots and store at −80°C)
GeltrexTM LDEV-Free Reduced Growth Factor Basement Membrane Matrix
(Thermo Fisher Scientific, cat. no. A1413202; defrost as per manufacturer’s
instructions; make stock aliquots and store at −20°C for up to 18 months from
date of manufacture; store unused diluted GeltrexTM Matrix solution, 1% final
concentration, at 4°C for up to 1 week)
Poly-L-ornithine solution (Merck Life Science, cat. no. P4957; store at 4°C; dilute
0.1mg/ml poly-L-ornithine stock solution with sterile cell culture grade water to
yield 20 μg/ml for plastic and 50 μg/ml for glass surfaces)
Cell culture grade water
ENS basal medium (see recipe, Table 7)
ENS complete culture medium (see recipe, Table 8)
CorningTM CostarTM Ultra-Low Attachment 6-well Microplates 3471 (Thermo
Fisher Scientific, cat. no. 10154431)
Biosafety cabinet
Incubator maintained at 37°C with 95% humidified atmosphere and 5% CO2 levels
Centrifuge (Thermo Fisher Scientific Heraeus Megafuge 1.0)
Inverted microscope (Olympus CKX41)
Fluorescence Olympus inverted microscope 1X53
InCell Analyser 2200 (GE Healthcare)
Single channel pipets and tips
Pipet controller and serological pipets
Cell culture plasticware and consumables: 15-, 50-ml conical tubes; multi-well













DMEM/F12 1× 0.5× 23.75 ml
Neurobasal 1× 0.5× 23.75 ml
B27 supplement 50× 1× 1 ml





100× 1× 0.5 ml
GlutaMAX
supplement
100× 1× 0.5 ml
a
Penicillin-streptomycin can be added in the basalmedium (final concentration 1×). Sphere basalmedium can be prepared
and stored at 4°C for 1 week.







concentration 10 ml 25 ml 50 ml
Sphere basal Not applicable Not applicable 10 ml 25 ml 50 ml
CHIR99021 10 mM 3 µΜ 3 µl 7.5 µl 15 µl
Recombinant
human FGF2
10 µg/ml 10 ng/ml 10 µl 25 µl 50 µl
Y-27632 2HCl 10 mM 10 µΜ 10 µl 25 µl 50 µl
a
We recommend using freshly made medium for sphere generation. Complete sphere culture medium is supplemented
with Y-27632 2HCl, a Rho-associated coil kinase (ROCK) inhibitor which increases cell survival and improves formation
of spheres (especially after breaking).











1× Not applicable 47.5 ml
B27 supplement 50× 1× 1 ml
N2 supplement 100× 1× 0.5 ml
MEM non-essential
amino acids solution
100× 1× 0.5 ml
GlutaMAX supplement 100× 1× 0.5 ml
a
Penicillin-streptomycin can be added in the basal medium (final concentration 1×). ENS basal medium can be prepared
and stored at 4°C for 1 week.
Prior to sphere formation
1. Prepare sphere basal culture medium (see Table 5).
2. Prepare complete sphere culture medium (see Table 6).




Table 8 ENS Complete Culture Medium
a
Final volume
Component Stock concentration Final concentration 10 ml 25 ml 50 ml
ENS basal Not applicable Not applicable 10 ml 25 ml 50 ml
Recombinant human GDNF 10 µg/ml 10 ng/ml 10 µl 25 µl 50 µl
DAPT 10 mM 10 µΜ 10 µl 25 µl 50 µl
Ascorbic acid 100 mM 100 µΜ 10 µl 25 µl 50 µl
a
Make ENS complete medium fresh before use. No ROCK inhibitor is added at the final plating.
We have used 1% agarose coated plates instead of the Corning ultra-low attachment
plates for sphere formation as well but the effect of the different conditions in sphere
architecture and expression was not thoroughly examined.
Sphere formation (3-4 days in total)
3. Day 6 (re-plating vagal neural crest into non-adherent conditions):
a. Aspirate medium from Day 6 vagal neural crest cells/early ENS progenitors care-
fully to avoid disturbing the monolayer on the bottom of the well.
b. Perform a quick wash with 1× PBS.
c. Lift cells into single-cell suspension by adding Accutase solution (100 µl per
cm2) and incubate at 37°C for 5-7 min.
d. Neutralize Accutase solution with pre-warmed DMEM/F12 and using a serologi-
cal pipet, triturate cell suspension a few times to ensure complete cell dissociation.
Do not aspirate Accutase solution at this step, as it contains cells that have been detached.
No need for counting cells; cells are plated down at a 1:1 ratio, e.g., the equivalent of a
well of a 6-well plate is transferred into a well of an ultra-low attachment plate.
e. Transfer cell suspension into a conical tube.
f. Place conical tube in a centrifuge and spin at 300 × g for 4 min at room temper-
ature.
g. Aspirate and discard supernatant very carefully without disturbing cell pellet.
h. Resuspend pellet in complete sphere culture medium (see Table 6).
For example: When a full 6-well plate of vagal neural crest cells/early ENS progenitors is
harvested for sphere formation, the resulting cell pellet is resuspended in 12 ml complete
sphere medium and 2 ml of cell suspension is transferred per well for subsequent plating.
i. Transfer cell suspension to each well of the 6-well ultra-low attachment plate.
That is, 2 ml of cell suspension transferred into each well of the non-adherent 6-well
plate.
Be gentle while transferring cells to the plate; avoid scraping the bottom of the well with
the pipet tip.
j. Place plates into a plate holder and centrifuge at 100 × g for 2 min at room tem-
perature.
This step collates single cells in the middle of the well to increase cell-cell contact and
assist sphere formation.
Following centrifugation, cell suspension is visible at the center of the well.
k. Incubate cells at 37°C for 24 hr.
Do not disturb plates for the first 24 hr.
4. Day 7 (24 hr after plating):




Floating cell aggregates appear in culture. They are quite fragile without well-defined
spherical shape yet.
Do not be alarmed by the increased cell death or number of single cells floating; many
of them will eventually form spheres in the next 24 hr.
b. Place plates in the incubator for another 24 hr.
5. Day 8 (48 hr after plating):
a. Spheres should be visible at this stage and have a better and/or round shape com-
pared to Day 7 (Fig. 4A).
b. Perform half medium change to supplement cells with fresh medium (see
Table 6).
i. Swirl plate to collect spheres from the circumference to the center of the well.
ii. Hold plate at an angle towards you and let spheres settle to form sediment at
the bottom corner of the well.
iii. Remove and discard 1 ml medium very carefully by placing the tip of a P1000
pipet at an angle facing the side of each well.
Do not aspirate all medium, as this increases the risk of losing cells, too.
Do not use a vacuum aspirator to perform medium change at this point; the suction force
is likely to cause sphere loss.
c. Incubate plates at 37°C for 24 hr.
6. Day 9 and Day 10:
a. Spheres are re-plated into neurotrophic medium for further differentiation to-
wards ENS derivatives.
b. If spheres have fused, forming large irregularly shaped aggregates, we prefer to
break them up into smaller spheres and culture them for an additional day prior
to culture in neurotrophic medium (see Troubleshooting, Table 10).
Transfer spheres to a 50-ml conical tube and triturate sphere suspension two to three
times by pipetting towards the side of the tube. We advise using a serological pipet with
wide tip opening, i.e., 10-ml stripette which is less harsh for the spheres.
Gentle handling of spheres is highly recommended; do not break the spheres too much,
as this will result in excessive cell death.
Prior to sphere plating
7. Prepare poly-L-ornithine/Geltrex coated plates:
Table 9 Antibodies Used for Characterization of ENS Components In Vitro
a
Antibody Company Catalog number Species Class
Anti-beta III
Tubulin (TuJ1)








Abcam ab8135 Rabbit Polyclonal
Anti-S100 (β-subunit) MilliporeSigma S2532 Mouse Monoclonal
Anti-HuC/HuD Invitrogen A-21271 Mouse Monoclonal
a




a. Coat plastic growth surface with 15 µg/ml poly-L-ornithine solution prepared in
cell culture grade water (50 µg/ml poly-L-ornithine solution is recommended for
glass surfaces); 200µl per cm2 is enough to cover the growth area. Incubate plates
for a minimum of 1 hr or overnight at 37°C.
b. Wash plates thoroughly twice using 1× PBS.
c. Aspirate 1× PBS and coat each well of the plate with diluted Geltrex solution
(1:100) as previously shown (Basic Protocol 1).
d. Let plates stand for 1 hr at 37°C.
8. Prepare ENS basal medium (see Table 7).
9. Prepare ENS complete medium (see Table 8).
Plating spheres into ENS induction medium (12 days and beyond)
10. Day 9 and Day 10:
a. Swirl plates and group spheres together at the center of the well.
b. Collect spheres in a 50-ml conical tube using a 10-ml serological pipet.
Sphere collection requires gentle handling to avoid breaking up the spheres, resulting in
single-cell suspension and concomitant reduced survival.
c. Let spheres settle to the bottom of the tube by gravity sedimentation for 5 min at
room temperature before proceeding to step d.
d. When the supernatant is clear and no cell aggregates are observed within the so-
lution, carefully remove and discard medium without disturbing sphere pellet.
Aspirating medium with a serological pipet or a P1000 pipet is highly recommended as
the suction force of an aspiration pump will disturb the pellet and result in sphere loss.
e. Resuspend sphere pellet using a 10-ml serological pipet in ENS complete culture
medium (see Table 8) and distribute sphere suspension to each well.
One well of spheres is resuspended in 3 ml of ENS complete culture medium and 1 ml
of sphere suspension is transferred to a well of a 12-well plate for subsequent enteric
neuron differentiation. For a 24-well plate, 0.5 ml of sphere suspension is transferred per
well.
The differentiation is much more robust when the cells are plated at a very high density
and deposited as whole spheres.
f. Move plates in a back-forth, right-left direction to distribute spheres evenly.
g. Incubate plates at 37°C for 48 hr.
Do not disturb plates for the first 24 hr.
After 24 hr, spheres have attached to the culture vessel and cells start migrating out of
them.
11. Day 11 and Day 12 (48 hr after plating spheres) and for the rest of the differentia-
tion:
a. Perform half medium change every other day by removing half of the old medium
from each well and replacing it with freshly made ENS complete culture medium.
b. Incubate cells at 37°C in a humidified atmosphere of 5% CO2 in air.
Increased cell death is expected during this stage of the differentiation. However, the wells
should remain confluent to allow neural induction to occur otherwise the differentiation
will fail.
Cells could be maintained in culture under ENS conditions for extended periods to allow





c. After day 30-35, perform half medium change biweekly (every 3-4 days) and
increase medium volume from 200 µl/cm2 to 400 µl/cm2.
If cells start dethatching or axons seem to wobble with plate movement, supplement
medium with vitronectin (1:100) once a week.
Understanding results
The neurons tend to form at regions of high density across the well, converge, and create
big clumps of neuronal cell bodies that are interconnected with axonal processes that span
the whole well (Fig. 4). Neurons first appear and migrate out of the spheres around day 12
of the protocol (2 days after culture in neurotrophic medium; Fig. 4B). Between day 17-
22, neural fibers are visible and cells express pan-neuronal markers such as neurofilament
heavy chain (NF-H), HuCD, TUJ1, PERIPHERIN, and TRKC (Fig. 4C and D), markers
widely used in the literature for enteric neuron characterization (Table 9). Glial cells
expressing S100β and SOX10 emerge around day 20-22 and grow in close vicinity to the
neuronal cell bodies (Fig. 4D). At this stage, the cell cultures are comprised of a mixture
of neural and glial cells that differentiate and mature further as the protocol progresses
(Fig. 4E). For a more detailed expression analysis of the generated neurons, refer to the
original study of Frith et al. (2020).We regularly observe emergence of contaminant cells
that lack the characteristic neuronal morphology and are not immunoreactive to ENS
lineage markers (ASCL1, PHOX2B, SOX10). These do not appear to influence negatively
the induction of neurons and/or glia.
REAGENTS AND SOLUTIONS
Complete sphere culture medium
See Table 6.
Enteric nervous system (ENS) basal medium
See Table 7.
Enteric nervous system (ENS) complete culture medium
See Table 8.
Neural crest basal medium
See Table 1.
Neural crest induction medium
See Table 2.




The in vitro generation of enteric neural
progenitors from hPSCs holds a great promise
for the development of cell-therapy-based ap-
proaches and the study of the specification
of ENS lineages and hence has attracted a
considerable amount of research interest. To
date, differentiation strategies have either im-
plemented embryoid body formation and cul-
ture of hPSC in the presence of EGF, FGF sig-
nals (Li et al., 2018; Workman et al., 2017)
or employed a monolayer differentiation ap-
proach that relies on transforming growth fac-
tor β (TGF-β) signaling suppression, bone
morphogenetic protein (BMP) signaling regu-
lation andWNT pathway stimulation to gener-
ate an NC-like population (Barber et al., 2019;
Lau et al., 2019). Patterning of the in vitro
derived NC to a vagal axial identity is rou-
tinely achieved by retinoic acid (RA) addition
(Barber et al., 2019; Lau et al., 2019; Work-
man et al., 2017) while further commitment
along the ENS trajectory has been mediated
by co-culture with intestinal (Workman et al.,Gogolou et al.
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2017)/colonic organoids (Lau et al., 2019), gut
tissue explants (Li et al., 2018), or further dif-
ferentiation following culture in neurotrophic
medium (Barber et al., 2019; Lau et al., 2019).
The protocol described here outlines an ef-
ficient method of directed differentiation that
generates ENS progenitors from hPSCs via a
vagal NC induction step following RA treat-
ment. The derivation of NC relies on the com-
bined WNT signaling stimulation and TFG-β
pathway inhibition together with precise lev-
els of BMP signaling. The latter is achieved
by the introduction of saturating levels of ex-
ogenous BMP which is titrated by the simul-
taneous addition of a BMP receptor inhibitor
(DMH-1) to counteract the effects of variable
endogenous BMP production and the con-
comitant variations in NC induction (Hack-
land et al., 2017). The resulting population,
which displays a cranial NC character (Frith
et al., 2018), is then further differentiated to-
ward a vagal NC/early ENS progenitor state
following exposure to RA in a dose-dependent
fashion (Frith et al., 2020). The obtained ENS
precursor population is marked by the expres-
sion of ASCL1, PHOX2B, SOX10, p75, and
CD49d. This approach is quicker than previ-
ously published protocols that yield equivalent
ENS progenitors after 10 to 15 days of hPSC
differentiation (Fattahi et al., 2016; Workman
et al., 2017) and crucially the ENS progenitors
can colonize the ENS of adult mice follow-
ing transplantation (Frith et al., 2020). They
can also be employed for the subsequent gen-
eration of electrophysiologically active enteric
neurons in vitro without the requirement for
an in vivo physical niche and instructive gut-
derived signals.
Critical Parameters
Directed differentiation of hPSCs can be
very challenging and often results in a great
variability in the protocol’s yield among inde-
pendent replicates or no induction at all (Fig.
3). We found that an inefficient vagal NC dif-
ferentiation is likely to reflect a poor qual-
ity hPSC starting population, a non-optimal
seeding density, or sometimes could be due to
inadequate medium change and the accom-
panied depletion of medium components es-
sential for the progression of the differentia-
tion. Thus, it is very important that attention
should be paid to these critical parameters, as
stated below, for a successful differentiation
outcome.
Quality of hPSC cultures
Culture of hPSCs should be performed fol-
lowing good laboratory practice guidelines.
Cultures should be monitored for bac-
terial and fungal contamination and should
be routinely examined for mycoplasma. To
avoid contamination, antibiotics such as gen-
tamycin or penicillin-streptomycin could be
added in the culture medium. Cell cultures
should be examined regularly for morphologi-
cal changes that indicate unwanted differentia-
tion. Spontaneously differentiated cells grown
in hPSC cultures impair differentiation effi-
ciency and therefore, their presence should be
eliminated by manual scraping. Screening for
markers such as NANOG, OCT4, SOX2 us-
ing qPCR or surface proteins SSEA4, SSEA3,
TRA-1-60, through flow cytometry, or im-
munostaining is highly recommended to as-
sess the presence of undifferentiated hPSCs
(Thomson et al., 1998; Wright & Andrews,
2009). Regular karyotyping of hPSCs should
also be employed to determine genetic aber-
rations that might occur during propagation of
stem cell cultures (Baker et al., 2016). We rou-
tinely culture hPSCs on Geltrex or vitronectin
coated flasks using mTeSRTM1 or Essential
8 medium and use ReLeSRTM as passaging
reagent. Alternative maintenance conditions
have not been tested and may affect the dif-
ferentiation efficiency of the current protocol.
We found that passaging cells using EDTA-
based dissociation solution yields lower NC
efficiency.
Seeding density
Seeding density determines NC efficiency
in a cell-line dependent manner. Therefore, it
is highly recommended that plating densities
for NC induction are optimized for each cell
line/end user.
Medium change
Induction and maintained expression of
ENS progenitor genes (ASCL1, PHOX2B) de-
pends on retinoic acid addition in NCmedium.
We found that daily medium replacement with
retinoic acid is required to retain high ASCL1,
PHOX2B transcript levels.
Troubleshooting
See Table 10 for common problems en-
countered when performing these protocols
and suggested solutions.
Time Considerations
Basic Protocol 1: 6 days.
Basic Protocol 2: 16 days or more. (To date,
we have kept enteric neurons alive until day





Table 10 Troubleshooting Table
Problem Possible cause Solution
Poor cell plating Geltrex solution is overdiluted or
has dried out or is not well
dispersed across the well
Cells are overgrown prior to NC
induction
Increase Geltrex concentration
Ensure growth surface area is fully coated
with Geltrex solution and it has not dried out
Harvest cells from a less confluent flask at
Day 0
Cells are not dispersed
uniformly on the surface
of the well following
plating
Inadequate agitation to distribute
cells
Tap plate gently in a “North, South, East,
West” direction to disperse cells evenly
across the surface of the well








Not precise levels of BMP
signaling
Poor quality hPSCs
Determine optimal seeding density at Day 0
(beginning of the protocol)
Prepare fresh NC medium and minimize
freeze-thaw cycles of small molecules
Titrate concentration of BMP4 and DMH-1
inhibitor for an optimal BMP signaling
activity
Assess quality of hPSCs
Inadequate vagal axial
patterning as determined
by expression of posterior
HOX genes
Infrequent medium change with
all-trans retinoic acid
Low all-trans retinoic acid
activity
Replace all-trans retinoic acid and ensure it
is stored appropriately
Inadequate ENS
specification on vagal NC
determined by the mRNA
levels of ASCL1, PHOX2B
Infrequent medium change with
all-trans retinoic acid
Low all-trans retinoic acid
activity
Refresh medium at Day 5 supplemented
with all-trans retinoic acid
Free floating spheres form
big “tube-like” structures
Increased cell numbers/well Triturate cell aggregates using a 10-ml
serological pipet by pipetting 2-3 times to
break them up into small spheres
No neurons observed Absence of small molecules or
low activity of growth factors
Poor induction of vagal
NC/early ENS progenitors
Spheres are broken up too much
prior to sphere plating
Not enough spheres/well
Prepare fresh ENS medium and minimize
freeze-thaw cycles of small molecules
Monitor/assess differentiation efficiency of
previous steps at Day 6 and Day 9/10
Determine optimal sphere resuspension
volume prior to plating for enteric neuron
differentiation; test different volumes/sphere
densities for plating
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